<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00049686</url>
  </required_header>
  <id_info>
    <org_study_id>VION-CLI-029</org_study_id>
    <secondary_id>CDR0000258354</secondary_id>
    <secondary_id>MDA-DM-02202</secondary_id>
    <nct_id>NCT00049686</nct_id>
  </id_info>
  <brief_title>VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome</brief_title>
  <official_title>A Phase I Trial Of VNP40101M, A Novel Alkylating Agent, For Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die.

      PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have
      relapsed or refractory leukemia or myelodysplastic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the toxic effects of VNP40101M in patients with relapsed or refractory
           leukemia or poor-risk myelodysplastic syndromes.

        -  Determine the maximum tolerated dose of this drug in these patients.

        -  Determine the pharmacokinetics of this drug in these patients.

        -  Determine the antitumor effects of this drug in these patients.

      OUTLINE: Patients receive VNP40101M IV over 15 minutes once every 4 weeks.

      PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>laromustine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Relapsed or refractory leukemia for which no standard therapy is anticipated to result
             in a durable remission OR

          -  Poor-risk myelodysplastic syndromes

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  AST and ALT no greater than 3 times ULN

        Renal

          -  Creatinine no greater than 2.0 mg/dL

        Cardiovascular

          -  No myocardial infarction within the past 3 months

          -  No symptomatic coronary artery disease

          -  No uncontrolled arrhythmia

          -  No uncontrolled congestive heart failure

        Other

          -  No uncontrolled active infection

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Prior biologic therapy allowed

        Chemotherapy

          -  At least 2 weeks since prior myelosuppressive cytotoxic chemotherapy in the absence of
             rapidly progressing disease

          -  At least 48 hours since prior hydroxyurea

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Prior radiotherapy allowed

        Surgery

          -  Not specified

        Other

          -  No other concurrent standard or investigational treatment for leukemia

          -  No concurrent disulfiram
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Sznol, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory cytopenia with multilineage dysplasia</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

